The status of pathogen-reduced plasma.

Area of Science:

• Blood safety
• Infectious disease control
• Biotechnology

Background:

• Blood transfusion safety has historically relied on laboratory testing for infectious agents.
• The increasing number of emerging pathogens and complex testing protocols present logistical challenges.
• Pathogen-reduction technologies (PRTs) are emerging as a novel approach to enhance blood safety.

Purpose of the Study:

• To review the current status of pathogen-reduced plasma products in the global market.
• To identify challenges and opportunities for the implementation of PRTs in blood banking.
• To discuss the economic implications of adopting PRTs.

Main Methods:

• Review of existing literature and market data on pathogen-reduction technologies.
• Analysis of the regulatory landscape for PRTs in different regions.
• Assessment of the technical feasibility and cost-effectiveness of PRTs for various blood components.

Main Results:

• Several PRTs have shown success for pooled plasma derivatives like immune globulins and albumin.
• Significant progress has been made in pathogen reduction for plasma products, with some available in Europe and the Middle East.
• No pathogen-reduced plasma product is currently approved by the US Food and Drug Administration (FDA).
• Challenges persist in developing suitable PRTs for red blood cells and platelets.

Conclusions:

• Pathogen-reduced plasma products are being implemented globally, but regulatory approval in the US is pending.
• The primary obstacle to widespread adoption in the US may be the cost associated with PRT implementation.
• Further research and development are needed to overcome technical and economic challenges for broader PRT application in transfusion medicine.